TJ Biopharma Reports P-II (PRIME-1) Data of Plonmarlimab for Macrophage Activation Syndrome

Shots: TJ Biopharma has announced publication of results from PRIME-1, a P-II study of plonmarlimab (anti-GM-CSF mAb) in macrophage activation syndrome (MAS), in the Journal of Hematology & Oncology In 18 glucocorticoid-refractory or relapsed MAS pts, Week-8 ORR was 83.3% (15/18), with median time to response of 2.1wks (earliest Day 5) & an LS-mean 79.3% reduction in glucocorticoid dose at Week 8 (83.3% achieved ≥50% reduction) Plonmarlimab was generally well tolerated, with no Grade ≥3 infections & no AEs leading to permanent discontinuation or death; it holds China’s NMPA Breakthrough Therapy Designation for MAS, with a P-III underway Ref: PR Newswire  |   Image: TJ Biopharma  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post TJ Biopharma Reports P-II (PRIME-1) Data of Plonmarlimab for Macrophage Activation Syndrome appeared first on PharmaShots.